Publication Month: Jun 2022 | Report Code: TIPRE00022453 | No. of Pages: 200 | Category: Biotechnology | Status: Published
The growing usage of mice models in virology and infectious diseases and the rising consumption of personalized medicine are bolstering the growth of the mice model market. Moreover, the rising advancements in gene editing tools are likely to emerge as a significant future trend in the mice model market during the forecast period. However, various regulations and laws for the ethical use of animals in research are hampering the overall market growth.
The mice have been used extensively as small animal models. Many genetically engineered mice models have emerged over the past two decades, and the emergence of gene-specific nucleases has accelerated their generation in recent years. Significant advances have been made in biotechnology, and the genetic engineering branch is advancing at an unprecedented rate, bringing numerous benefits. Genome editing technology has revolutionized genetic and biological research by providing a novel ability to precisely manipulate and modify the genomes of living organisms and accelerating the study of functional genomics. Various genome editing tools have recently been used to study simple and complicated genomes. The development of meganuclease-engineered zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the CRISPR-Cas9 system have undoubtedly revolutionized genome editing and opened up new possibilities, particularly in rats and other species in which embryonic stem cells (ESC) were not available.
CRISPR/Cas9 genome editing for the production of mice models of human disease has changed the field due to numerous benefits, including time savings, reduction in animal consumption, and overall cost efficiencies. CRISPR, known as Clustered Regularly Interspaced Short Palindromic Repeats, Associated Protein (Cas9) technology, has revolutionized genome editing. Several novel applications of CRISPR/Cas9 across a wide range of diseases have demonstrated its efficacy and have been used significantly in vivo mice models. For example, the application of viral-mediated delivery of the CRISPR system to adult mouse somatic cells has led to the development of an Eml4-Alk-driven lung cancer mouse model to study disease characteristics. Moreover, transgenic mice were created by incorporating Cas9 into mouse zygotes to understand the pathophysiology of cardiovascular diseases. The CRISPR-Cas9 system was also used to generate Kcnj13 mutant mice to study ocular diseases. The technology has also helped researchers create different types of immunodeficient mice models.
The application of CRISPR/CAS 9 to edit the β-globin gene has successfully increased fetal hemoglobin levels to treat sickle cell disease in mice. Similarly, in September 2021, the Washington University School of Medicine researchers used a mice model to study the behavior of cells engineered with CRISPR to treat rheumatoid arthritis. The cells responded to mouse inflammatory cytokines and released an anti-cytokine biological drug in the model cells. Therefore, companies such as Synthego and Cyagen are offering CRISPR-edited mice models to take advantage of the growing possibilities of CRISPR technology.
Such aforementioned factors are expected to boost the growth of the mice model market from 2022 to 2028.
North America is likely to continue its dominance in the mice model market from 2022 to 2028. The region is anticipated to witness substantial demand for mice models over the forecast period, aided by the presence of key market players and the growth in the pharmaceutical & research sectors in this region. The ongoing research and development in the healthcare sector for the development of regenerative medicine and tissue engineering are also supporting the North America mice model market. The US held the largest market share in the North American market from 2022 to 2028and is expected to grow in the coming years owing to the increasing adoption of technological advancements and rising emphasis on improving treatment outcomes. The mice model market in the US is expected to grow due to the high prevalence of chronic diseases, such as diabetes and viral infections. The presence and dominance of contract research organizations (CROs) in the country incorporating animal models into their research and the increasing focus on personalized medicines are key factors expected to increase the demand for mice models in the US. Further, continuous research and development in the healthcare sector for the development of regenerative medicine and tissue engineering are increasing the need for mice models in the country. Moreover, the rising prevalence of diseases is forcing the government to focus on preventive measures, which is increasing the investment in clinical trials using animal models. For instance, in March 2020, the FDA spent ~US$ 250,000 testing SARS-CoV-2 on animal models. The presence of established industry players and state-of-the-art healthcare facilities in the country will further fuel the demand for mice models. Such aforementioned factors are driving the growth of the mice model market.
Get more information on this report :
Based on end user, the mice model market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and others. In 2022, the academic and research institutes segment held the largest share of the market and is expected to register the highest CAGR from 2022 to 2028.
Get more information on this report :
Companies operating in the mice model market adopt the product innovation strategy to meet the evolving customer demands worldwide, which also permits them to maintain their brand name in the global mice model market.
Based on type, the mice model market is categorized inbred mice, outbred mice, genetically engineered mice, hybrid mice, surgically modified mice, and spontaneous mutant mice. Based on service, the market is segmented into breeding, cryopreservation, model-in licensing, genetic testing, quarantine, and others. Based on technology, the market is segmented into CRISPR, microinjection, embryonic stem cell injection, nuclear transfer, and others. Based on indication, the market is categorized into oncology studies, immunology & inflammation studies, endocrine metabolic studies, cardiovascular studies, central nervous system (CNS) studies, genetic studies, infectious disease studies, fibrosis, and other disease studies. Based on application, the market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. Based on mode, the market is bifurcated into in-house and outsourced. Based on end user, the mice model market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and others.By geography, the mice model market is primarily segmented into North America, Europe, Asia Pacific, Middle East & Africa (MEA), and South & Central America. The market in North America is further segmented into the US, Canada, and Mexico. The European mice model market is sub segmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The market in Asia Pacific is sub segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. The mice model market in the MEA is further segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The mice model market in South & Central America is further segmented into Brazil, Argentina, and the Rest of SAM.
Charles River Laboratories; The Jackson Laboratory; Taconic Biosciences, Inc; TRANS GENIC INC.; GenOway S.A.; Envigo; Janvier Labs; Ozgene Pty Ltd.; Crown Bioscience Inc.; and Harbour BioMed are among the leading companies operating in mice model market.
The List of Companies - Mice Model Market
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.